Further studies exploring the functional consequences of aggregate-selective versus total tau depletion, alongside long-term toxicity profiling, will inform the feasibility of R-Nb constructs as a therapeutic modality against tau and other aggregating proteins in neurodegenerative diseases. The gene discussed is MAPT; the disease is neurodegenerative disease.